Isotopia backs development of 'virtual' biopsy

By staff writers

April 29, 2021 -- Isotopia Molecular Imaging has announced it is backing research led by Israeli investigators who are developing a radiopharmaceutical to detect small, aggressive cancerous tumors.

The research is focused on a hypoxia radioactive marker based on a copper-64 isotope that reportedly identifies oxygen-deficient cells. Studies have shown that oxygen concentration in the cell is directly related to the aggressiveness of cancerous tumors.

The hypoxia radioactive marker may determine if a tumor is malignant or benign and also show how aggressive it is through a single image, eliminating the need for a standard biopsy, the company said in a release.

The research is led by Sharon Ruthstein, PhD, of the department of chemistry at Bar-Ilan University in Ramat Gan.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking